CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Long term follow-upother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03022461
NCT03022461N/ACompleted

HeartMate 3 CE Mark Study Long Term Follow-up Clinical Investigation Plan

Abbott Medical Devices·observational·Posted Jan 16, 2017·Updated Jun 27, 2022

In Brief

An observational study evaluating Long term follow-up for Advanced Refractory Left Ventricular Heart Failure. Completed, enrolled 25 participants across 8 sites in 6 countries.

Detailed Summary

The purpose of this clinical investigation is to report the long term survival and incidence of adverse events in the patients who were implanted with HM3 in the CE Mark Study and continue to be ongoing with the HeartMate 3 LVAS after the CE Mark Study 2 year follow-up. The study will be a single arm, prospective, multi-center, non-blinded and non-randomized study, intended to report on the long term use of the HeartMate 3 LVAS in those patients that completed the 2-year follow-up in the HeartMate 3 CE Mark study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Canada, Czechia, Germany, Kazakhstan
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 16, 2017
Enrollment StartJun 23, 2014
Primary CompletionDec 12, 2019
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 9.5 years ago

Interventions

Long term follow-upother